A thyroid cancer diagnosis can feel overwhelming. But here is something many patients do not expect to hear from their surgeon: not all thyroid cancers require aggressive treatment. In fact, the management of thyroid cancer has changed fundamentally over the past decade — away from a one-size-fits-all approach and towards care that is carefully tailored to your individual risk profile.
This shift is backed by robust clinical evidence and reflected in the most recent international guidelines from the American Thyroid Association (2025). For many patients, this means less surgery, no radioactive iodine, and a structured monitoring programme rather than immediate intervention. For others with higher-risk disease, new targeted therapies offer options that simply did not exist a few years ago.
Here is what the current evidence says — and what it means for you.
1. What is differentiated thyroid cancer?
The thyroid is a butterfly-shaped gland at the base of the neck that regulates metabolism, heart rate, and body temperature through the hormones it produces. Thyroid cancer arises from its cells, and “differentiated” thyroid cancer (DTC) — the most common form — originates from the follicular cells responsible for hormone production.
Within this category, the two main subtypes are papillary thyroid cancer (PTC), which accounts for approximately 85–90% of cases and is typically slow-growing and highly treatable, and follicular thyroid cancer, which is less common with a slightly different pattern of spread. For most patients with DTC confined to the neck, the five-year survival rate exceeds 98%. This excellent prognosis is one of the reasons why treatment decisions are now far more nuanced — aggressive treatment for a low-risk cancer may cause more harm than the cancer itself.
2. Why has thyroid cancer treatment changed?
For many years, the standard approach for most thyroid cancers was total removal of the thyroid gland (total thyroidectomy), followed routinely by radioactive iodine (RAI) therapy. This approach made sense before we had reliable ways to distinguish low-risk from higher-risk disease.
What changed is our understanding of thyroid cancer biology. Large long-term studies demonstrated that many thyroid cancers — particularly small papillary cancers — grow extremely slowly, often do not spread, and may never cause clinical harm during a patient’s lifetime. Two landmark clinical trials — the IoN trial and the ESTIMABL2 trial — demonstrated that patients with low-risk differentiated thyroid cancer do just as well without radioactive iodine as those who receive it. This evidence has driven a global shift towards de-escalation of treatment for appropriately selected patients.
3. What does risk-adapted management mean for you?
Risk-adapted management means that your treatment plan is built around your individual circumstances, not a standard protocol applied to everyone. When your surgeon assesses your thyroid cancer, they consider tumour size and position, whether lymph nodes are involved, the specific histological subtype, molecular and genetic characteristics of the tumour, and your age, overall health, and personal preferences.
This assessment does not happen just once. It is ongoing — a process called dynamic risk stratification. Your initial risk category may change after surgery when the pathology results are available, and again over time as your surveillance results return. Treatment recommendations are adjusted accordingly.
4. Could you avoid surgery? Understanding active surveillance
For small papillary thyroid cancers measuring 1 cm or less without high-risk features, active surveillance — careful monitoring with regular neck ultrasound rather than immediate surgery — is now a recognised, evidence-based option in international guidelines.
Long-term studies involving thousands of patients in Japan and the United States have shown that the vast majority of these microcarcinomas do not grow significantly or spread during extended follow-up. A systematic review and meta-analysis of 5,685 patients confirmed 100% disease-specific survival, with distant metastasis occurring in only 0.03% of patients. Surgery is recommended if the cancer shows signs of growth, if new lymph node involvement develops, or if you decide you would prefer definitive surgical treatment.
Active surveillance is not doing nothing. It is a structured, closely monitored programme requiring regular specialist appointments, ultrasound assessments, and blood tests. The decision requires a detailed conversation with your surgeon about your specific tumour characteristics and your own values and preferences.
5. Do you need radioactive iodine after surgery?
Radioactive iodine (RAI) was historically given after thyroid surgery to destroy any remaining thyroid tissue and microscopic cancer cells. Current evidence from the IoN and ESTIMABL2 randomised trials has established that low-risk DTC patients achieve equivalent long-term outcomes without RAI.
Current guidelines now recommend RAI selectively — for patients with higher-risk tumour features (large size, extrathyroidal extension, lymph node or distant metastases), aggressive histological subtypes, or incomplete surgical resection. If RAI is recommended in your case, your specialist will explain the specific reasons based on your pathology results.
6. When is more intensive treatment needed?
While many patients will be managed with a de-escalated approach, some cancers require more extensive treatment. Features that may indicate this include tumours larger than 4 cm, spread to lymph nodes or distant sites, radioactive iodine-resistant disease, or aggressive histological variants.
For patients with advanced or RAI-refractory differentiated thyroid cancer, a new generation of targeted therapies has transformed the treatment landscape. Depending on the genetic profile of your tumour, options include selpercatinib for RET-altered cancers, larotrectinib for NTRK fusion cancers, dabrafenib and trametinib for BRAF V600E-positive anaplastic thyroid cancer, and multikinase inhibitors lenvatinib or sorafenib for RAI-refractory disease. Molecular testing of your tumour tissue is therefore an important step in advanced disease.
Key Takeaways
- Thyroid cancer is highly treatable — most patients with neck-confined disease have a five-year survival exceeding 98%
- Modern management is personalised to your individual risk, not a one-size-fits-all protocol
- Small, low-risk papillary thyroid cancers may be safely monitored without immediate surgery (active surveillance)
- Many patients with low-risk disease do not require radioactive iodine after surgery
- Risk assessment is dynamic: your treatment plan may evolve as new information becomes available
- Advanced or RAI-refractory disease now has effective targeted therapies based on your cancer’s genetic profile
- Shared decision-making — your values, preferences, and circumstances — is central to modern thyroid cancer care
Clinical Notes for Referring Doctors
The following summary is intended for general practitioners and referring specialists.
- The 2025 American Thyroid Association guidelines support risk-adapted, de-escalated management for low-risk DTC
- Active surveillance is appropriate for papillary thyroid microcarcinoma (≤1 cm) without high-risk features (lymph node metastasis, extrathyroidal extension, high-risk molecular markers)
- Lobectomy — rather than total thyroidectomy — is the recommended surgical procedure for unifocal, intrathyroidal tumours <4 cm without clinical lymph node involvement
- RAI ablation is not recommended for low-risk DTC following total thyroidectomy (IoN trial; ESTIMABL2 trial)
- Post-operative surveillance is guided by thyroglobulin (Tg), anti-Tg antibody (TgAb), and neck ultrasound; interval and intensity are tailored to risk category
- Molecular testing (RET fusions/point mutations, NTRK fusions, BRAF V600E, RAS) should be considered in locally advanced, recurrent, or metastatic disease to guide systemic therapy selection
- Referral to a high-volume thyroid cancer centre is recommended for all patients with locally advanced, recurrent, or distant metastatic disease
Enquiries and referrals: Dr Justin James, Endocrine & Breast Surgery — via rooms or drjustinjames.com.au
References & Disclosure
This blog post is based on the following peer-reviewed sources:
1. Hegedüs L, Wirth LJ, Tuttle RM. Management of Differentiated Thyroid Cancer. N Engl J Med 2026;394:2340–55. DOI: 10.1056/NEJMra2416814
2. Nguyen VC, Song CM, Ji YB, et al. Outcomes and effectiveness of active surveillance for low-risk papillary thyroid carcinoma: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2025;282:2239–52.
3. Miyauchi A, Ito Y, Fujishima M, et al. Long-term outcomes of active surveillance and immediate surgery for adult patients with low-risk papillary thyroid microcarcinoma: 30-year experience. Thyroid 2023;33:817–25.
References 2 and 3 are cited within reference 1. The active surveillance data draws on long-term cohorts from Japan (Kuma Hospital, Osaka) and the United States (Memorial Sloan Kettering Cancer Center, New York).
Disclosure: The content of this blog is intended for general educational purposes only and does not constitute medical advice. It is based on current evidence and clinical guidelines, and has been reviewed by Dr Justin James (FRACS), Endocrine and Breast Surgeon. It should not replace individualised advice from your treating specialist. If you have concerns about your thyroid health, please consult your doctor.
